secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001437749-24-005802
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics reports Q4 2023 BRIUMVI net revenue $39.9M; 2024 target $220-260M
--------------------------------------------------------------------------------

- BRIUMVI U.S. net revenue $39.9M in Q4 2023, $88.8M for full year 2023.
- Net loss of $14.4M in Q4; net income of $12.7M for full year 2023.
- Year-end cash $217.5M; 2024 BRIUMVI net revenue target $220-260M; operating expense ~$250M.
- License revenue $141.7M in 2023 driven by $140M Neuraxpharm payment for ex-U.S. rights.
- Pipeline: subcutaneous BRIUMVI, azer-cel CAR T in autoimmune disease to start trials in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774924005802/0001437749-24-005802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774924005802/tgtx20240227_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-005802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer